This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pathology & Laboratory Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Therapeutic Implications

Thomas W. Sedlak, MD, PhD; Solomon H. Snyder, MD

JAMA. 2006;295:81-89.

Programmed cell death, also called apoptosis, participates not only in normal physiologic processes such as development of the immune system, but also in many diseases. A loss of normal cell death may occur in cancer, and excessive cell death is found in a variety of neurodegenerative conditions. We describe 3 distinct pathways that regulate cell death. First, bilirubin, often thought to be a toxic end product of heme metabolism, serves as a physiologic cytoprotectant that may attenuate multiple forms of morbidity. In a second pathway, the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mediates a novel cell death cascade. Cytotoxic stimuli, via nitric oxide generation, lead to the binding of GAPDH to the protein Siah1, translocation of GAPDH-Siah1 to the nucleus, and ultimately cell death. Third, cytochrome c, released from mitochondria early in apoptosis, synergizes with inositol-1,4,5-triphosphate (IP3) to elicit massive cellular calcium release, resulting in cell death. These pathways may regulate cell survival in a variety of pathologic states and represent fertile targets for novel therapies.

Author Affiliations: Departments of Neuroscience and Psychiatry and Behavioral Sciences (Drs Sedlak and Snyder) and Pharmacology and Molecular Sciences (Dr Snyder), Johns Hopkins School of Medicine, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells
Kalota and Gewirtz
Blood 2010;115:89-93.
ABSTRACT | FULL TEXT  

Mitochondrial Na+/Ca2+-Exchanger Blocker CGP37157 Protects against Chromaffin Cell Death Elicited by Veratridine
Nicolau et al.
J. Pharmacol. Exp. Ther. 2009;330:844-854.
ABSTRACT | FULL TEXT  

Signaling by Gasotransmitters
Mustafa et al.
Sci Signal 2009;2:re2-re2.
ABSTRACT | FULL TEXT  

The Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation
Innamorato et al.
J. Immunol. 2008;181:680-689.
ABSTRACT | FULL TEXT  

A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping
Fujarewicz et al.
Endocr Relat Cancer 2007;14:809-826.
ABSTRACT | FULL TEXT